Output details
15 - General Engineering
King's College London
Article title
A phase II study of ¹⁸F-fluorodeoxyglucose PET-CT in non-small cell lung cancer patients receiving erlotinib (Tarceva®); objective and symptomatic responses at 6 and 12 weeks
Type
D - Journal article
Title of journal
European Journal of Cancer
Article number
-
Volume number
48
Issue number
1
First page of article
68
ISSN of journal
1879-0852
Year of publication
2012
URL
-
Number of additional authors
11
Additional information
A prospective trial showing the value of 18F-FDG PET in predicting response to biological therapy in lung cancer. The study showed that 18F-FDG PET was able to predict treatment response, and in particular determine patients not responding to treatment, at an early time point, such that patients can be spared ineffective treatment and potential side effects. Cook was the PI on the grant, and responsible for the PET component of the study.
Interdisciplinary
-
Cross-referral requested
-
Research group
None
Proposed double-weighted
No
Double-weighted statement
-
Reserve for a double-weighted output
No
Non-English
No
English abstract
-
